Zur Rose Group AG
ROSE | SW
Overview
Corporate Details
- ISIN(s):
- CH0042615283 (+1 more)
- LEI:
- 50670038OH136R5Z4663
- Country:
- Switzerland
- Address:
- Walzmühlestrasse 49, 8500 Frauenfeld
- Sector:
- Health Care
- Industry:
- Health Care Equipment & Supplies
Description
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand, DocMorris With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It also excels in continuous development of digital healthcare services and as a platform technology provider. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up its European healthcare ecosystem networking qualified providers of products, services and digital solutions.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-17 10:31 |
Regulatory News Service
DocMorris launches prescription bonus save up to 15
|
English | 3.8 KB | |
| 2025-07-17 02:00 |
Regulatory News Service
DocMorris AG: Federal Court of Justice confirms admissibility of prescription b…
|
English | 7.8 KB | |
| 2025-07-17 02:00 |
Regulatory News Service
DocMorris AG: BGH bestätigt Zulässigkeit von Rezept-Boni
|
German | 8.2 KB | |
| 2025-07-15 07:00 |
Regulatory News Service
gematik extends DocMorris CardLink approval until January 2027
|
English | 7.2 KB | |
| 2025-07-15 02:00 |
Regulatory News Service
gematik extends DocMorris CardLink approval until January 2027
|
English | 5.9 KB | |
| 2025-07-15 02:00 |
Regulatory News Service
gematik verlängert DocMorris CardLink Zulassung bis Januar 2027
|
German | 6.2 KB | |
| 2025-06-11 11:18 |
Regulatory News Service
Obesity therapy support programme from DocMorris
|
English | 6.1 KB | |
| 2025-05-22 17:40 |
Share Issue/Capital Change
DocMorris AG announces number of shares sold in rights offering
|
English | 12.7 KB | |
| 2025-05-21 02:00 |
Share Issue/Capital Change
DocMorris AG announces number of shares sold in rights offering
|
English | 11.4 KB | |
| 2025-05-21 02:00 |
Share Issue/Capital Change
DocMorris AG gibt das Ergebnis ihres Bezugsrechtsangebots bekannt
|
German | 12.1 KB | |
| 2025-05-20 13:30 |
Major Shareholding Notification
Pelion invests in DocMorris
|
English | 11.8 KB | |
| 2025-05-14 09:00 |
Regulatory News Service
DocMorris: Aktuelle Kantar-Verbraucherbefragung zeigt weiter steigende Beliebth…
|
German | 4.8 KB | |
| 2025-05-09 20:28 |
Share Issue/Capital Change
DocMorris AG shareholders approve capital increase and all proposals put forwar…
|
English | 15.6 KB | |
| 2025-05-08 06:58 |
General Meeting Notice
DocMorris announces final details on the agenda of today's Annual General Meeti…
|
English | 23.0 KB | |
| 2025-05-08 00:00 |
Quarterly Report
Quarterly Report Q1 2025
|
English | 129.6 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-20 | N/A | Non-Executive member | Buy | None | 175,188.00 CHF |
| 2025-05-20 | N/A | Non-Executive member | Buy | None | 28,818.00 CHF |
| 2025-05-19 | N/A | Executive member | Buy | None | 34,500.00 CHF |
| 2025-05-19 | N/A | Non-Executive member | Buy | None | 14,040.00 CHF |
| 2025-05-19 | N/A | Executive member | Buy | None | 9,142.50 CHF |
| 2025-05-16 | N/A | Non-Executive member | Buy | None | 1,035,000.00 CHF |
| 2025-05-16 | N/A | Executive member | Buy | None | 46,400.00 CHF |
| 2025-05-16 | N/A | Executive member | Buy | None | 10,315.50 CHF |
| 2025-05-16 | N/A | Non-Executive member | Buy | None | 8,616.00 CHF |
| 2025-05-15 | N/A | Executive member | Buy | None | 678,770.25 CHF |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. | Türkiye | GENIL | |
|
Gvs | Italy | GVS | |
|
Haleon PLC | United Kingdom | HLN | |
|
I.Ceram | France | ALICR | |
|
NanoRepro AG | Germany | NN6 | |
|
PolyPeptide Group AG | Switzerland | PPGN | |
|
Safe S.A. | France | ALSAF | |
|
Sartorius Stedim Biotech | France | DIM | |
|
SKAN Group AG | Switzerland | SKAN | |
|
Slavej AD | North Macedonia | SLAV |